Canaccord analyst Edward Nash reiterated a Buy rating and $5.00 price target on Rani Therapeutics (NASDAQ: RANI).The analyst commented: "Rani ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE